А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

August 20, 2019

Study Completion Date

November 1, 2019

Conditions
Anxiety Disorder Generalized
Interventions
DRUG

CD-008-0045

CD-008-0045 20 mg capsules

DRUG

Placebo

Placebo capsules

Trial Locations (15)

Unknown

"Clinical Center LLC Center for Psychotherapy Support", Stavropol

"Research Center for Mental Health Scientific Institution", Moscow

"Clinical Center LLC University Headache Clinic", Moscow

"Moscow Research Institute of Psychiatry National Medical Research Center for Psychiatry and Narcology named after V.P. Serbsky", Moscow

Nizhny Novgorod Clinical Psychiatric Hospital No.1, Nizhny Novgorod

"Clinical Center LLC TREATMENT AND REHABILITATION RESEARCH CENTER PHOENIX ", Rostov-on-Don

Ryazan Medical University, Department of Psychiatry, Ryazan

"Clinical Center LLC Doctor SAN", Saint Petersburg

"Clinical Center LLC Dynasty", Saint Petersburg

Leningrad Regional Psychoneurological Dispensary, Saint Petersburg

"St. Petersburg Psychoneurological dispensary #5", Saint Petersburg

"Clinical Center LLC LION-MED", Voronezh

"Clinical Center LLC Medical practice", Voronezh

Yaroslavl Regional Psychiatric Hospital, Yaroslavl

"Clinical Center JSC Medical Technologies", Yekaterinburg

All Listed Sponsors
lead

ChemRar Research and Development Institute, LLC

INDUSTRY

NCT04524975 - А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter